Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug

At a Thursday Senate health committee meeting, FDA commissioner nominee Heidi Overton was asked about mifepristone and, according to the author, evaded the question. The author, CEO of Reproductive Futures, says Overton’s anti-abortion views are clear and that as FDA commissioner she could implement policies causing serious harm. Anti-abortion groups cheered the nomination as a chance to remove access to mifepristone, and the head of Americans United for Life said he had spoken with Overton five or six times and predicted she would “expose this drug.” The author frames the situation as mifepristone having a new boss but an old problem.

Second, the piece argues that few medications have been sued, petitioned against, or hauled before Congress as often as mifepristone. For two decades, the U.S. has probed, cross-examined, and disparaged the drug despite well-documented safety, the author writes, and even under that scrutiny its safety and efficacy record remains strong in the U.S. and globally.

Third, drawing on more than a decade as a human rights lawyer working with women in Ireland to challenge that country’s complete abortion ban, the author describes the “Irish journey”: traveling by ferry or flight to England, sometimes with borrowed money, often in isolation, and always with unnecessary hardship. That work inspired Reproductive Futures, which brings legal firepower to help patients access abortion through telemedicine and avoid an “American journey.” The author notes that the vast majority of all abortion now relies on mifepristone, and that patients should not have to travel to a clinic to receive the same safe, effective medications they could receive at home.

Fourth, mifepristone, paired with misoprostol, is standard care around the world; an estimated 7.5 million Americans have used it, and the American College of Obstetricians and Gynecologists recommends it for early pregnancy loss as well. Yet the FDA has never added miscarriage management to its label, leaving miscarriage patients tangled in the same medically unnecessary red tape. The author says Thursday’s hearing indicated birth control may be next. The restrictions include FDA requirements that clinicians be specially certified to prescribe mifepristone, a unique pharmacy registration system that keeps most pharmacies from dispensing it even in abortion-friendly states, and a special patient agreement form that adds another layer of exposure and bureaucracy. The author calls this unneeded rigmarole for a safe drug with a comparatively very low rate of reported deaths over its decades of use.